SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02334865 |
|
Recruitment Status :
Active, not recruiting
First Posted : January 8, 2015
Last Update Posted : December 14, 2022
|
Sponsor:
Roswell Park Cancer Institute
Collaborator:
Celgene
Information provided by (Responsible Party):
Roswell Park Cancer Institute
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Estimated Primary Completion Date : | January 30, 2023 |
| Estimated Study Completion Date : | November 9, 2023 |